N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Indiana University
Sponsor:
Collaborator:
BioAdvantex Pharma
Information provided by (Responsible Party):
Samir K Gupta, MD, MS, Indiana University
ClinicalTrials.gov Identifier:
NCT01962961
First received: October 11, 2013
Last updated: April 28, 2014
Last verified: April 2014

October 11, 2013
April 28, 2014
October 2013
January 2015   (final data collection date for primary outcome measure)
  • Circulating malondialdehyde levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Measure of oxidative stress
  • Circulating F2-isoprostane levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Oxidative stress measure
  • Flow-mediated dilation (FMD) of the brachial artery [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Measure of endothelial function
Same as current
Complete list of historical versions of study NCT01962961 on ClinicalTrials.gov Archive Site
Adverse events [ Time Frame: 4 week and 8 weeks ] [ Designated as safety issue: Yes ]
Safety measures of PharmaNAC given at two different doses
Same as current
Not Provided
Not Provided
 
N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy

The goal of this study is to determine if n-acetylcysteine, given as PharmaNAC, reduces oxidative stress and improves vascular function in HIV-infected older adults already on HIV treatment.

The primary objective of this study is to compare 8-week changes in circulating levels of malondialdehyde (MDA), circulating levels of F2-isoprostanes, and flow-mediated dilation (FMD) of the brachial artery in older HIV-infected adults already receiving virologically suppressive antiretroviral therapy (ART) who are then randomized to either NAC 900 mg twice daily, NAC 1800 mg twice daily, or placebo. The relative efficacy and safety of these two doses of NAC will be assessed.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • HIV
  • Endothelial Dysfunction
  • Oxidative Stress
  • Dietary Supplement: PharmaNAC (N-acetylcysteine)

    PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.

    PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).

    Other Names:
    • N-acetylcysteine
    • NAC
  • Dietary Supplement: Matching placebo
  • Experimental: PharmaNAC 1800 mg
    PharmaNAC 900 mg orally twice daily for 8 weeks
    Interventions:
    • Dietary Supplement: PharmaNAC (N-acetylcysteine)
    • Dietary Supplement: Matching placebo
  • Experimental: PharmaNAC 3600 mg
    PharmaNAC 1800 mg orally twice daily for 8 weeks
    Intervention: Dietary Supplement: PharmaNAC (N-acetylcysteine)
  • Placebo Comparator: Placebo
    Matching placebo pills given twice daily for 8 weeks
    Intervention: Dietary Supplement: Matching placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
June 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or (2) by two detectable HIV-1 antigens, or (3) two detectable plasma HIV-1 RNA viral loads.
  • Age equal to or greater than 50 years.
  • Receipt of antiretroviral therapy of any kind for at least 6 months prior to screening.
  • HIV-1 RNA level < 75 copies/mL at screening.
  • For women who are still of reproductive potential, a negative urine pregnancy test at screening and willingness to use two forms of birth control during the course of the study. Acceptable forms of birth control include condoms (with or without a gel that can kill sperm), a diaphragm or cervical cap (with or without a gel that can kill sperm), an intrauterine device (IUD), or hormonal-based birth control ("the pill").

Exclusion Criteria:

  • Inability to complete written, informed consent.
  • Incarceration at the time of any study visit.
  • Known allergy or intolerance to n-acetylcysteine.
  • Use of n-acetylcysteine within 180 days of screening.
  • Diagnosed vascular disease (history of angina pectoris, coronary disease, peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known atherosclerotic disease).
  • History of congestive heart failure even if currently compensated.
  • History of portal hypertension or hepatic cirrhosis (either clinically diagnosed or histologically diagnosed).
  • Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosis, inflammatory bowel diseases, other collagen vascular diseases).
  • Known or suspected malignancy requiring systemic treatment within six months of screening.
  • History of ADA-defined diabetes mellitus (115)
  • History of migraine headaches.
  • History of Raynaud's phenomenon.
  • History of cardiac arrhythmias or cardiomyopathy.
  • Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the local reference range on most recent clinical assessment.
  • Asthma or COPD requiring daily use of beta-2-agonist therapy (e.g. albuterol)
  • History of carotid bruits.
  • Creatinine clearance < 50 mL/min (using the Cockcroft-Gault equation) using a serum creatinine level measured at screening.
  • Hemoglobin < 9.0 g/dL at screening.
  • Alanine aminotransferase (ALT) level or aspartate aminotransferase (AST) > 3 times ULN at screening.
  • Total bilirubin > 2.5 times ULN at screening; if the participant is receiving atazanavir, then s/he would be excluded if total bilirubin is > 3.5 times ULN at screening.
  • Therapy for serious medical illnesses within 14 days prior to screening.
  • Pregnancy or breastfeeding during the course of the study.
  • Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening.
  • Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (of any dose), or anabolic steroids at screening.
  • Previous receipt of stavudine or didanosine for more than 7 cumulative days.
  • Receipt of daily Vitamin C or Vitamin E supplements at screening.
  • Alcohol intake more than the equivalent of one 8 oz. of wine daily for the 7 days prior to screening.
  • Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Both
50 Years and older
No
Contact: Paula Johnson, NP 317-278-2945 johnpaul@iu.edu
United States
 
NCT01962961
IU SRI 1306011647
Yes
Samir K Gupta, MD, MS, Indiana University
Indiana University
BioAdvantex Pharma
Principal Investigator: Samir K Gupta, MD, MS Indiana University School of Medicine
Indiana University
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP